Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
Madeleine Hazard(Hôpital Dupuytren), E. Gérard(Université de Bordeaux), M. Beylot‐Barry(Université de Bordeaux), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Charlée Nardin(CHU Dijon Bourgogne), S. Prey(Université de Bordeaux), Safia Abed(Hôpital d'Instruction des Armées Sainte-Anne), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), F. Aubin(Centre Hospitalier Universitaire de Besançon), Mona Amini‐Adlé(Centre Léon Bérard), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Valentine Heidelberger(Assistance Publique – Hôpitaux de Paris), M. Saint‐Jean, Fanny Duval, Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Amir Khammari(Inserm), G. Quéreux(Nantes Université), Brigitte Dréno(Nantes Université)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k